A detailed history of Pathstone Holdings, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Pathstone Holdings, LLC holds 6,249 shares of ALNY stock, worth $1.52 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,249
Previous 5,620 11.19%
Holding current value
$1.52 Million
Previous $1.37 Million 25.86%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$233.81 - $287.01 $147,066 - $180,529
629 Added 11.19%
6,249 $1.72 Million
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $252,512 - $435,214
1,762 Added 45.67%
5,620 $1.37 Million
Q1 2024

May 13, 2024

BUY
$146.51 - $198.2 $142,700 - $193,046
974 Added 33.77%
3,858 $576,000
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $436,666 - $566,907
2,884 New
2,884 $552,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.